Clinical effect of irinotecan in advanced and metastatic breast cancer patients previously treated with doxorubicin- and docetaxel-containing regimens

Japanese Journal of Clinical Oncology

Volumn 31, Issue 8, 2001, Pages 370-374

  Shigeoka, Yasushi ^a   Itoh, Kuniaki ^a   Igarashi, Tadahiko ^a   Ishizawa, Kenichi ^a   Saeki, Toshiaki ^a   Fujii, Hirofumi ^a   Minami, Hironobu ^a   Imoto, Shigeru ^a   Sasaki, Yasutsuna ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Breast cancer; Chemotherapy; Drug resistance; Irinotecan; Salvage treatment

Indexed keywords

ANTHRACYCLINE; CREATININE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IRINOTECAN; MITOMYCIN C; TAXANE DERIVATIVE; VINBLASTINE;

ADULT; ANEMIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; HYPERSENSITIVITY REACTION; LEUKOPENIA; PREMEDICATION; PRIMARY HEALTH CARE; RETROSPECTIVE STUDY; SALVAGE THERAPY; SECONDARY PREVENTION;

EID: 0034798071     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/hye082     Document Type: Article

References (21)

1. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyl-oxycamptotecin, a novel water soluble derivative of camptothecin, against murine tumors
2. A phase II study of a new camptothecin analogue CPT-11 in previously treated advanced breast cancer patients
3. An early phase II study of CPT-11 (irinotecan hydrochloride) in patients with advanced breast cancer
4. A late phase II study of CPT-11 in advanced breast cancer
5. A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer
6. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy
7. Nonparametric estimation from incomplete observations
8. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
9. Randomised trial of irinotecan plus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
10. Treatment of breast cancer
11. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
12. Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511)
13. Phase II study of irinotecan in prior chemotherapy treated squamous cell carcinoma of the cervix
14. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo
15. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody
16. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan
17. Topoisomerase I inhibitors: Review and update
18. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients